This is an EU sponsored trial and independent of the US trial registered under Clinicaltrials.gov ID NCT02009644. The purpose of this registry is to gather clinical data on the safety and performance of the TREO Stent-Graft in patients with infrarenal abdominal aortic aneurysms. The registry is part of TREO's EU post-market surveillance plan providing long-term systematic clinical follow-up.
This is a prospective, multicenter, post-market clinical follow-up, non-randomized registry of the TREO Stent-Graft. Subjects diagnosed with infrarenal aortic aneurysms and treated with the TREO Stent-Graft or TREO aorto-uni-iliac (AUI) device can be included into the registry. Pre-procedure baseline data will be gathered as well as post-procedure assessments prior to hospital discharge and one to three months and 1, 2, 3, 4, and 5-year post-implantation. The objective of the registry is to assess the clinical results and health economics of the TREO device in a real-world population of patients with infrarenal abdominal aortic aneurysms (AAA).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
174
The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
Imelda Hospital
Bonheiden, Belgium
Imeldaziekenhuis
Bonheiden, Belgium
AZ Sint Blasius
Dendermonde, Belgium
Aneurysm-related mortality
Time frame: 30 days post-procedure
Stroke (excluding transient ischemic attack)
Time frame: 30 days post-procedure
Myocardial infarction
Raised cardiac enzymes within 30 days of the procedure
Time frame: 30 days post-procedure
Renal failure
Renal failure requiring renal replacement therapy (excluding renal insufficiency)
Time frame: 30 days post-procedure
Respiratory failure
excluding chronic obstructive pulmonary disease or pulmonary complications)
Time frame: 30 days post-procedure
Paraplegia
(excluding paraparesis)
Time frame: 30 days post-procedure
Bowel ischemia
A restriction in blood supply to tissues in the bowels
Time frame: 30 days post-procedure
Treated aneurysm rupture
Time frame: 30 days post-procedure
Major Adverse Events (MAE) at the follow-up time points
MAE includes any of the following : Aneurysm-related mortality, Stroke (excluding transient ischemic attack), Myocardial infarction, Renal failure requiring renal replacement therapy (excluding renal insufficiency), Respiratory failure (excluding chronic obstructive pulmonary disease or pulmonary complications), Paraplegia (excluding paraparesis), Bowel ischemia, Treated aneurysm rupture
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bonifatius Hospital
Lingen, Germany
University Clinic and St. Franziskus Hospital Muenster
Münster, Germany
University Hospital Tübingen
Tübingen, Germany
Compensorio Sanitario Bolzano
Bolzano, Italy
UMC Groningen
Groningen, Netherlands
UMCU
Utrecht, Netherlands
Hospital Clinic Barcelona
Barcelona, Spain
...and 6 more locations
Time frame: 30 days post-procedure
Limb Ischemia
Rate of clinically-evident ischemia, subcategorized by embolism or thrombosis, tabulated by the frequency of major amputation.
Time frame: 30 days post-procedure
Secondary procedures
Freedom from aneurysm-related secondary procedures through five years follow-up. A questionnaire will be conducted. Investigators are required to conduct a lesion and device assessment at each follow-up visit. All secondary procedures reported will be treated descriptively in terms of results.
Time frame: 5 years
Vascular access complications
Injuries to vessels as a result of the endovascular procedure.
Time frame: Vascular access will be evaluated on day of index procedure (implant)
Patient-reported quality of life (QOL)
Health outcomes using the EuroQol Five Dimensions Questionnaire (EQ-5D) standardized EuroQol instrument.
Time frame: One year follow-up